LINE250117P75000
- 16.70
- 0.000.00%
Lineage Newsroom
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
Lineage Cell Therapeutics Analyst Ratings
Lineage Cell Price Target Lowered to $2 From $3 at D. Boral Capital
Daily short sale tracking: Intel's short volume increased by 4 million, with a short sale ratio of 18%
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $95
Lineage To Go Ex-Dividend On December 31st, 2024 With 0.5275 USD Dividend Per Share
Is Lineage, Inc. (LINE) the Best New Stock to Buy According to Hedge Funds?
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $95
Positive Outlook and Strategic Positioning Drive Buy Rating for Lineage, Inc.
Wall Street's IPO Engine Picked Up in 2024 -- Barrons.com
Stocks Ride Inflation Optimism Into Holiday Week. Why This Is Peak Good Cheer.
Real Estate Stocks End in Red With the Pace of Rate Cuts Expected to Slow in 2025
J.P. Morgan Downgrades Lineage(LINE.US) to Hold Rating, Cuts Target Price to $75
J.P. Morgan Downgrades Lineage, Inc. (LINE) to a Hold
J.P. Morgan Revises Ratings on Five REITs Ahead of 2025
Lineage Price Target Cut to $75.00/Share From $78.00 by JP Morgan
Lineage Cut to Neutral From Overweight by JP Morgan
JP Morgan Downgrades Lineage to Neutral, Lowers Price Target to $75
Lineage Analyst Ratings
InterVision Wins First-Ever AWS GenAI Builder Bonanza Contest, Demonstrating Excellence in AI Sovereignty and Data Lineage